Crosstalk between tumor cells and lymphocytes modulates heparanase expression
Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies h...
Saved in:
Published in | Journal of translational medicine Vol. 17; no. 1; pp. 103 - 14 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
29.03.2019
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes.
Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR.
The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer.
The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. |
---|---|
AbstractList | Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Methods Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. Results The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. Conclusions The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. Keywords: Tumor microenvironment, Breast neoplasms, HPSE, HPSE2, Heparan sulfate, Proteoglycans Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes.BACKGROUNDHeparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes.Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR.METHODSLymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR.The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer.RESULTSThe medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer.The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes.CONCLUSIONSThe results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. Abstract Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Methods Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. Results The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. Conclusions The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Methods Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. Results The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. Conclusions The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote angiogenesis, tumor growth and metastasis. Heparanase-2 (HPSE2), a close homolog of HPSE, does not exhibit catalytic activity. Previous studies have demonstrated that serum or plasma from breast cancer patients showed increased expression of both heparanases in circulating lymphocytes. The aim of this study was to better understand the mechanisms involved in the upregulation of heparanases in circulating lymphocytes. Lymphocytes collected from healthy women were incubated in the presence of MCF-7 breast cancer cells (co-culture) to stimulate HPSE and HPSE2 overexpression. The protein level of heparanases was evaluated by immunocytochemistry, while mRNA expression was determined by quantitative RT-PCR. The medium obtained from co-culture of MCF-7 cells and circulating lymphocytes stimulated the expression of HPSE and HPSE2. Previous treatment of the co-culture medium with an anti-heparan sulfate proteoglycan antibody or heparitinase II inhibited the upregulation of heparanases in circulating lymphocytes. The addition of exogenous heparan sulfate (HS) enhanced the expression of both heparanases. Moreover, the co-cultured cells, as well as MCF-7 cells, secreted a higher number of exosomes expressing an increased level of HS compared to that of the exosomes secreted by circulating lymphocytes from women who were not affected by cancer. The results revealed that HS is likely responsible for mediating the expression of heparanases in circulating lymphocytes. HS secreted by tumor cells might be carried by exosome particles, confirming the key role of tumor cells, as well as secreted HS, in upregulating the expression of heparanases, suggesting a possible mechanism of crosstalk between tumor cells and circulating lymphocytes. |
ArticleNumber | 103 |
Audience | Academic |
Author | Theodoro, Thérèse Rachell Justo, Giselle Zenker Matos, Leandro Luongo Pinhal, Maria Aparecida Silva Cavalheiro, Renan Pelluzzi Nader, Helena Bonciani |
Author_xml | – sequence: 1 givenname: Thérèse Rachell surname: Theodoro fullname: Theodoro, Thérèse Rachell – sequence: 2 givenname: Leandro Luongo surname: Matos fullname: Matos, Leandro Luongo – sequence: 3 givenname: Renan Pelluzzi surname: Cavalheiro fullname: Cavalheiro, Renan Pelluzzi – sequence: 4 givenname: Giselle Zenker surname: Justo fullname: Justo, Giselle Zenker – sequence: 5 givenname: Helena Bonciani surname: Nader fullname: Nader, Helena Bonciani – sequence: 6 givenname: Maria Aparecida Silva surname: Pinhal fullname: Pinhal, Maria Aparecida Silva |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30922347$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ustu1DAUjVARfcAHsEGR2LBJ8dvxBqka8ahUxAbWlmPfzHhI7MFOgPbrcZhSOhVCXtyr63POfeicVkchBqiq5xidY9yK1xkTJWSDsGpwy2lz86g6wUyqhrdSHN3Lj6vTnLcIEcaZelIdU6QIoUyeVB9XKeY8meFr3cH0AyDU0zzGVFsYhlyb4Orhetxtor2eINdjdPNglmwDO5NMMBlq-LlLkLOP4Wn1uDdDhme38az68u7t59WH5urT-8vVxVVjuUBTY1lvesopVx2THeCeO0YpcDDGIIQFEr1UAmGJTQkOqLOt7J0hDknRG0TPqsu9rotmq3fJjyZd62i8_l2Iaa1NmrwdQBPMOEadItJhBn1pISUhnCDbKSuwLVpv9lq7uRvBWQhTMsOB6OFP8Bu9jt-1YFQpJYrAq1uBFL_NkCc9-ryczwSIc9aEICRbLuky98sH0G2cUyinKiiMWcuFav-i1qYs4EMfS1-7iOoL3mJKVcsX1Pk_UOU5GL0tRul9qR8QXtxf9G7DP2YoALwH2MUTCfo7CEZ6MZzeG04Xw-nFcPqmcOQDjvWTmYoXyjR--A_zF1ms2hU |
CitedBy_id | crossref_primary_10_3390_cancers13061441 crossref_primary_10_1016_j_semcancer_2019_07_014 crossref_primary_10_3390_cancers13194798 crossref_primary_10_1016_j_oraloncology_2020_104909 crossref_primary_10_3390_biomedicines12061190 crossref_primary_10_1080_14712598_2020_1813276 crossref_primary_10_4103_jcrt_jcrt_1072_22 crossref_primary_10_1038_s41419_021_03825_2 crossref_primary_10_1186_s12967_020_02624_1 crossref_primary_10_3390_molecules25020390 crossref_primary_10_3390_ijms21207802 |
Cites_doi | 10.1080/03008200802143281 10.1111/febs.12168 10.1186/s13058-018-0995-x 10.1002/jcb.20602 10.1593/neo.07241 10.3389/fonc.2013.00231 10.18632/oncotarget.16575 10.1006/bbrc.2000.3586 10.1001/jamaoncol.2017.2140 10.1074/jbc.M111.330803 10.1080/23723556.2015.1047556 10.1016/j.tibs.2017.10.007 10.1172/JCI45817 10.1186/1471-2407-13-444 10.1016/0304-4165(87)90016-X 10.1038/cmi.2011.47 10.1007/s00281-018-0689-6 10.1074/jbc.C112.444562 10.1007/s10549-018-5043-0 10.1590/S1807-59322006000500008 10.1371/journal.pone.0204513 10.1016/j.cell.2011.02.013 10.1016/S0021-9258(17)44833-2 10.1038/nrc2618 10.1038/s41388-018-0128-0 10.1074/jbc.M611259200 10.3390/cells7100167 10.1093/neuonc/nov170 10.1038/cr.2015.29 10.1007/978-3-319-95294-9_4 10.1016/j.matbio.2017.09.001 10.1073/pnas.1304266110 10.1016/j.exphem.2016.08.006 10.1016/0304-4165(74)90237-2 10.1016/j.bbrc.2017.02.060 10.1038/ncb2502 10.1371/journal.pone.0010135 10.1186/s12943-014-0279-8 10.1111/febs.12111 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2019 |
Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2019 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12967-019-1853-z |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 14 |
ExternalDocumentID | oai_doaj_org_article_214510b927d14efeaa7722520cb9c61c PMC6439996 A581339858 30922347 10_1186_s12967_019_1853_z |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | California |
GeographicLocations_xml | – name: California |
GrantInformation_xml | – fundername: ; grantid: 2016/01357-8 |
GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c560t-c4faf35359b47be1f5d433e5eaaa001606f7960171a960de3dc87fda2d076fa03 |
IEDL.DBID | M48 |
ISSN | 1479-5876 |
IngestDate | Wed Aug 27 01:23:40 EDT 2025 Thu Aug 21 18:38:33 EDT 2025 Fri Jul 11 07:08:11 EDT 2025 Fri Jul 25 19:55:21 EDT 2025 Tue Jun 17 21:07:30 EDT 2025 Tue Jun 10 20:20:03 EDT 2025 Thu Apr 03 06:59:03 EDT 2025 Tue Jul 01 03:51:11 EDT 2025 Thu Apr 24 23:12:32 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Heparan sulfate Breast neoplasms Proteoglycans HPSE HPSE2 Tumor microenvironment |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c560t-c4faf35359b47be1f5d433e5eaaa001606f7960171a960de3dc87fda2d076fa03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2211485698?pq-origsite=%requestingapplication% |
PMID | 30922347 |
PQID | 2211485698 |
PQPubID | 43076 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_214510b927d14efeaa7722520cb9c61c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6439996 proquest_miscellaneous_2200785730 proquest_journals_2211485698 gale_infotracmisc_A581339858 gale_infotracacademiconefile_A581339858 pubmed_primary_30922347 crossref_primary_10_1186_s12967_019_1853_z crossref_citationtrail_10_1186_s12967_019_1853_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-03-29 |
PublicationDateYYYYMMDD | 2019-03-29 |
PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-29 day: 29 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of translational medicine |
PublicationTitleAlternate | J Transl Med |
PublicationYear | 2019 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | D Hanahan (1853_CR11) 2011; 144 Z Wan (1853_CR19) 2018; 8 I Vlodavsky (1853_CR40) 2018; 43 T Shtam (1853_CR20) 2018 CA Thompson (1853_CR27) 2013; 288 LL Matos (1853_CR33) 2006; 61 HB Nader (1853_CR35) 1990; 265 HC Lim (1853_CR39) 2015; 14 M Bellone (1853_CR16) 2013; 3 AK Simi (1853_CR1) 2018; 1092 G David (1853_CR30) 2015; 3 VC Ramani (1853_CR10) 2013; 280 B Roucourt (1853_CR29) 2015; 25 Y Yang (1853_CR8) 2007; 282 K Harano (1853_CR14) 2018; 13 ER Suarez (1853_CR37) 2013; 13 YM Michelacci (1853_CR34) 1987; 923 M Bitan (1853_CR17) 2010; 5 M Nawaz (1853_CR24) 2018; 7 MF Baietti (1853_CR26) 2012; 14 E Zhao (1853_CR12) 2012; 9 RD Sanderson (1853_CR3) 2005; 96 CP Dietrich (1853_CR32) 1974; 345 TR Theodoro (1853_CR18) 2007; 9 C Chute (1853_CR2) 2018; 20 JA Joyce (1853_CR21) 2009; 9 HC Christianson (1853_CR28) 2013; 110 I Vlodavsky (1853_CR4) 2008; 49 S Yu (1853_CR7) 2017; 485 T Karn (1853_CR13) 2017; 3 MW Graner (1853_CR22) 2018; 40 W Jiao (1853_CR5) 2018; 37 JE Hellwinkel (1853_CR23) 2015; 18 B Heyman (1853_CR31) 2016; 44 H Hassan (1853_CR38) 2013; 280 SK Bandari (1853_CR9) 2018; 65 H Salmon (1853_CR15) 2012; 122 VC Ramani (1853_CR25) 2012; 287 X Sun (1853_CR36) 2017; 8 E McKenzie (1853_CR6) 2000; 3 |
References_xml | – volume: 49 start-page: 207 year: 2008 ident: 1853_CR4 publication-title: Connect Tissue Res doi: 10.1080/03008200802143281 – volume: 280 start-page: 2294 year: 2013 ident: 1853_CR10 publication-title: FEBS J doi: 10.1111/febs.12168 – volume: 20 start-page: 66 year: 2018 ident: 1853_CR2 publication-title: Breast Cancer Res doi: 10.1186/s13058-018-0995-x – volume: 96 start-page: 897 year: 2005 ident: 1853_CR3 publication-title: J Cell Biochem doi: 10.1002/jcb.20602 – volume: 9 start-page: 504 year: 2007 ident: 1853_CR18 publication-title: Neoplasia. doi: 10.1593/neo.07241 – volume: 3 start-page: 231 year: 2013 ident: 1853_CR16 publication-title: Front Oncol. doi: 10.3389/fonc.2013.00231 – volume: 8 start-page: 43521 year: 2017 ident: 1853_CR36 publication-title: Oncotarget. doi: 10.18632/oncotarget.16575 – volume: 3 start-page: 1170 year: 2000 ident: 1853_CR6 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2000.3586 – volume: 3 start-page: 1707 year: 2017 ident: 1853_CR13 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2017.2140 – volume: 287 start-page: 9952 year: 2012 ident: 1853_CR25 publication-title: J Biol Chem doi: 10.1074/jbc.M111.330803 – volume: 3 start-page: e1047556 year: 2015 ident: 1853_CR30 publication-title: Mol Cell Oncol. doi: 10.1080/23723556.2015.1047556 – volume: 43 start-page: 18 year: 2018 ident: 1853_CR40 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2017.10.007 – volume: 122 start-page: 899 year: 2012 ident: 1853_CR15 publication-title: J Clin Invest. doi: 10.1172/JCI45817 – volume: 13 start-page: 444 year: 2013 ident: 1853_CR37 publication-title: BMC Cancer. doi: 10.1186/1471-2407-13-444 – volume: 923 start-page: 291 year: 1987 ident: 1853_CR34 publication-title: Biochim Biophys Acta doi: 10.1016/0304-4165(87)90016-X – volume: 9 start-page: 11 year: 2012 ident: 1853_CR12 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.47 – volume: 40 start-page: 505 year: 2018 ident: 1853_CR22 publication-title: Semin Immunopathol. doi: 10.1007/s00281-018-0689-6 – volume: 288 start-page: 10093 year: 2013 ident: 1853_CR27 publication-title: J Biol Chem doi: 10.1074/jbc.C112.444562 – year: 2018 ident: 1853_CR20 publication-title: Breast Cancer Res Treat. doi: 10.1007/s10549-018-5043-0 – volume: 61 start-page: 417 year: 2006 ident: 1853_CR33 publication-title: Clinics. doi: 10.1590/S1807-59322006000500008 – volume: 13 start-page: e0204513 year: 2018 ident: 1853_CR14 publication-title: PLoS ONE doi: 10.1371/journal.pone.0204513 – volume: 8 start-page: 1661 year: 2018 ident: 1853_CR19 publication-title: Am J Cancer Res. – volume: 144 start-page: 646 year: 2011 ident: 1853_CR11 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 265 start-page: 16807 year: 1990 ident: 1853_CR35 publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)44833-2 – volume: 9 start-page: 239 year: 2009 ident: 1853_CR21 publication-title: Nat Rev Cancer doi: 10.1038/nrc2618 – volume: 37 start-page: 2728 year: 2018 ident: 1853_CR5 publication-title: Oncogene doi: 10.1038/s41388-018-0128-0 – volume: 282 start-page: 13326 year: 2007 ident: 1853_CR8 publication-title: J Biol Chem doi: 10.1074/jbc.M611259200 – volume: 7 start-page: E167 issue: 10 year: 2018 ident: 1853_CR24 publication-title: Cells. doi: 10.3390/cells7100167 – volume: 18 start-page: 497 year: 2015 ident: 1853_CR23 publication-title: Neuro-Oncology. doi: 10.1093/neuonc/nov170 – volume: 25 start-page: 412 year: 2015 ident: 1853_CR29 publication-title: Cell Res doi: 10.1038/cr.2015.29 – volume: 1092 start-page: 57 year: 2018 ident: 1853_CR1 publication-title: Adv Exp Med Biol doi: 10.1007/978-3-319-95294-9_4 – volume: 65 start-page: 104 year: 2018 ident: 1853_CR9 publication-title: Matrix Biol doi: 10.1016/j.matbio.2017.09.001 – volume: 110 start-page: 17380 year: 2013 ident: 1853_CR28 publication-title: PNAS doi: 10.1073/pnas.1304266110 – volume: 44 start-page: 1002 year: 2016 ident: 1853_CR31 publication-title: Exp Hematol doi: 10.1016/j.exphem.2016.08.006 – volume: 345 start-page: 34 year: 1974 ident: 1853_CR32 publication-title: Biochim Biophys Acta doi: 10.1016/0304-4165(74)90237-2 – volume: 485 start-page: 432 year: 2017 ident: 1853_CR7 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2017.02.060 – volume: 14 start-page: 677 year: 2012 ident: 1853_CR26 publication-title: Nat Cell Biol doi: 10.1038/ncb2502 – volume: 5 start-page: e10135 year: 2010 ident: 1853_CR17 publication-title: PLoS ONE doi: 10.1371/journal.pone.0010135 – volume: 14 start-page: 15 year: 2015 ident: 1853_CR39 publication-title: Mol Cancer. doi: 10.1186/s12943-014-0279-8 – volume: 280 start-page: 2216 year: 2013 ident: 1853_CR38 publication-title: FEBS J doi: 10.1111/febs.12111 |
SSID | ssj0024549 |
Score | 2.3020513 |
Snippet | Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE promote... Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated by HPSE... Abstract Background Heparanase (HPSE) is an endo-beta-glucuronidase that degrades heparan sulfate (HS) chains on proteoglycans. The oligosaccharides generated... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 103 |
SubjectTerms | Angiogenesis Antibodies Biosynthesis Bone marrow Breast cancer Breast neoplasms Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer cells Cancer metastasis Cancer therapies Cell adhesion & migration Cell Communication - drug effects Cell Communication - physiology Cell culture Cell growth Cells, Cultured Coculture Techniques Culture Media, Conditioned - pharmacology Exosomes Extracellular matrix Female Gene expression Gene Expression Regulation, Enzymologic - drug effects Gene Expression Regulation, Neoplastic - drug effects Glucuronidase - genetics Glucuronidase - metabolism Growth factors Health aspects Heparan sulfate Heparitin Sulfate - metabolism Heparitin Sulfate - physiology HPSE HPSE2 Humans Immunocytochemistry Lymphocyte Activation - genetics Lymphocytes Lymphocytes - metabolism Lymphocytes - physiology MCF-7 Cells Messenger RNA Metastases Metastasis Oligosaccharides Polymerase chain reaction Proteoglycans Receptor Cross-Talk - drug effects Receptor Cross-Talk - immunology Risk factors RNA Stem cells Sulfates Tumor cells Tumor microenvironment Tumors Women's health |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFB6kD8UX0dZLtMoIgiCEZjK3zGMtllJYnyz0bZgrFdtEurtg--s9J5ldNgj64lNCZkIyZ87lO5uz3yHkg5K-c5mZWmkha8Ed-EEvWC1lSJ0TsXFjm87FV3V-KS6u5NVOqy-sCZvogSfBHSOTNmu8aXVkIuXkHODBVrZN8CYoFtD7QszbJFMblj1Ie8o3TNap4yVENYUllqbG-FQ_zKLQSNb_p0veiUnzesmdAHT2lDwpyJGeTG_8jDxK_QHZX5Rv44dkcYqPAiz9g5biK7pa3w53FH-bX1LXR3pzD3s3hHuAl_R2iNi5C86uE_J_9xDOaPpV6mL75-Ty7Mu30_O6NEuoA4CWVR1EdplLLo0X2ieWZRScJwkCc2MzaZU1ZCtMMweHmHgMnc7RtbHRKruGvyB7_dCnV4TyMRNzLfctmLhy3iSVwRkAVtMesteKNBvh2VCYxLGhxY0dM4pO2UneFuRtUd72oSKftrf8nGg0_jb5M-7IdiIyYI8XQC9s0Qv7L72oyEfcT4t2Ci8XXPm7ASwRGa_siewgPTed7CpyNJsJ9hXmwxuNsMW-l7ZtMY-UysDw--0w3ok1a30a1jgH8ZcEF1qRl5MCbZfEGwO4TOiK6JlqzdY8H-m_X4_s3wghIUl9_T-E9IY8btEoGuznd0T2Vnfr9BZA1sq_G-3pN-AkIsc priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS9xAFD60Fkpfir0atSWFQqEQTDLXPImVihS2TxX2bZhbaqkmdi-g_nrPyc6uhoJPG3YmJDNzLt-ZOfkOwGcpnLZt1RRScVFwZtEOOl4VQvioLQ-lHcp0Tn7K0zP-YyqmacNtntIq1zZxMNSh97RHflDXhNyFbPTh1b-CqkbR6WoqofEUnhF1GUm1mt4HXByDn3SSWWl5MEffJinRsinISxW3I180UPb_b5gfeKZx1uQDN3SyDS8TfsyPVgv-Cp7E7jU8n6QT8jcwOaZHIaL-m6cUrHyxvOxnOe3Qz3PbhfziBlew9zcIMvPLPlD9Lrw6j8QC3qFTy-N1yo7t3sLZyfdfx6dFKplQeIQui8Lz1rZMMNE4rlysWhE4Y1FEa-1QUlq2CmOWSlUWf0JkwWvVBluHUsnWluwdbHV9F3cgZ0M8ZmvmalR0aV0TZYsmARGbchjDZlCuJ8_4xCdOZS0uzBBXaGlW821wvg3Nt7nN4OvmlqsVmcZjnb_Rimw6Eg_28Ec_-22SWhniWa9K19QqVDy2OEyMFmpRl941XlY-gy-0noa0FV_O2_TRAQ6ReK_MkdAYpDda6Az2Rz1Ry_y4eS0RJmn53NzLZAafNs10J2WudbFfUh9CYQINaQbvVwK0GRIrG0RnXGWgRqI1GvO4pftzPnCAE5DEUHX38dfagxc1iXtJ9fr2YWsxW8YPCKIW7uOgKXc67Rq_ priority: 102 providerName: ProQuest |
Title | Crosstalk between tumor cells and lymphocytes modulates heparanase expression |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30922347 https://www.proquest.com/docview/2211485698 https://www.proquest.com/docview/2200785730 https://pubmed.ncbi.nlm.nih.gov/PMC6439996 https://doaj.org/article/214510b927d14efeaa7722520cb9c61c |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3ri9NAEB_uAeIX8W30LBEEQYjmsY_kg8j1uOMQeshhofhl2d1sPLGXaB9wvb_eme22XvAQ_NKU7ibpzM7rt5nMALwW3JS6yapESMYTVmi0g4ZlCefWlZrVqfZtOkdn4nTMPk34ZAc27a0CA-e3QjvqJzWeTd9d_Vp9RIX_4BW-FO_n6LMEJVBWCXmf5HoX9tExSWpoMGLln9J73EfDGZNVwtEKhIect16i56Z8Nf-_bfYNp9VPqLzhoU7uw70QWsaHa1l4ADuufQh3RuHh-SMYHdGtkM4fccjOihfLy24W0-b9PNZtHU9XuLidXWH8GV92NbX2wm8XjgqEt-jvYncVEmfbxzA-Of5ydJqEbgqJxahmkVjW6KbgBa8Mk8ZlDa9ZUTjutNa-27RoJMKZTGYaD7UralvKptZ5nUrR6LR4Antt17pnEBcequm8MDnaAKFN5USD1gKDOWkQ3kaQbpinbCg1Th0vpspDjlKoNb8V8lsRv9V1BG-3p_xc19n41-Qhrch2IpXI9j90s28qaJyiEuxZaqpc1hlzDZKJQCLneWpNZUVmI3hD66lItPDPWR3eR0ASqSSWOuQl4veq5GUEB72ZqIC2P7yRCLWRX5XnBDS5qHD41XaYzqSkttZ1S5pDARpHGxvB07UAbUkq0goDNyYjkD3R6tHcH2m_X_jy4BRjIop9_j8cfQF3cxL-lBr7HcDeYrZ0LzHaWpgB7MqJHMD-8Pjs8_nA71kMvF7h5_nw628WHShZ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIgEXxBtDASOBkJCs2vuyfUCoFKqUNj21Um7Ler2miNYueQjSH8VvZMZep7WQeuspUXadeGfn8X3Z8QzAGyWLzFRJHqlUyEhwg36wEEkkpXWZEWVs2jad4wM1OhJfJ3KyBn_7Z2EorbL3ia2jLhtL_5FvMkbIXao8-3j2K6KuUXS62rfQ6NRizy1_I2Wbfdj9jPv7lrGdL4fbo8h3FYgsRvd5ZEVlKi65zAuRFi6pZCk4d9IZY9quy6pKEdYnaWLwpXS8tFlalYaVSPkrE3P83htwEwNvTGQvnVwQPIFky5-cJpnanGEsVZTYmUcUFaPzQexrWwT8HwguRcJhlualsLdzD-56vBpudQp2H9Zc_QBujf2J_EMYb9NPIYL_GfqUr3C-OG2mIZ0IzEJTl-HJEjWmsUsEteFpU1K_MHx37KjqeI1BNHR_fDZu_QiOrkWYj2G9bmr3FELe8j_DeMHQsShT5E5V6IIQIaYFcuYA4l542vr65dRG40S3PCZTupO3Rnlrkrc-D-D96pKzrnjHVZM_0Y6sJlLd7faDZvpdezPWVNc9iYucpWUiXIXLRHbCJIttkVuV2ADe0X5q8g54c9b4hxxwiVRnS2_JLOE8z2QWwMZgJlq1HQ73GqG9V5npCxsI4PVqmK6kTLnaNQuaQ6hPouMO4EmnQKsl8ThHNCjSANKBag3WPBypfxy3NccJuCI1fnb1bb2C26PD8b7e3z3Yew53GKl-TL0CN2B9Pl24Fwjg5sXL1mpC-HbdZvoPiQpX_g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Crosstalk+between+tumor+cells+and+lymphocytes+modulates+heparanase+expression&rft.jtitle=Journal+of+translational+medicine&rft.au=Theodoro%2C+Th%C3%A9r%C3%A8se+Rachell&rft.au=Matos%2C+Leandro+Luongo&rft.au=Cavalheiro%2C+Renan+Pelluzzi&rft.au=Justo%2C+Giselle+Zenker&rft.date=2019-03-29&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-019-1853-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12967_019_1853_z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |